Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Muzastotug - Adagene

Next Previous
X
Search
Drug Profile

Muzastotug - Adagene

Alternative Names: ADG-126; Anti-CTLA-4 monoclonal antibody; Masked anti-CTLA-4 SAFEbody

Latest Information Update: 29 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adagene
  • Developer Adagene; Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer; Solid tumours
  • Clinical Phase Unknown Cancer

Most Recent Events

  • 25 Jul 2024 Efficacy and adverse event data from the phase Ib/II KEYNOTE-C98 trial in Solid tumours released by Adagene
  • 17 May 2024 Adagene completes a phase I/II trial in Solid tumours (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in Singapore, Australia, USA (IV) (NCT04645069)
  • 17 May 2024 Adagene completes a phase I/II trial in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease, Second-line therapy or greater) in Singapore, Australia, USA (IV) (NCT04645069)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top